Butterfly Network Earnings Call Highlights AI-Led Growth

Butterfly Network, Inc. ((BFLY)) has held its Q1 earnings call. Read on for the main highlights of the call.

Butterfly Network’s latest earnings call struck an overall upbeat tone, with management underscoring accelerating growth, expanding margins, and significant AI and regulatory milestones. Executives also acknowledged ongoing losses, cash burn, and execution risks, but argued that a strong balance sheet and disciplined investment leave the company well positioned for scalable long‑term opportunities.

Robust Revenue Growth Across U.S. and International Markets

Butterfly reported first‑quarter revenue of $26.5 million, a 25% year‑over‑year increase, supported by broad‑based demand for its handheld ultrasound solutions. U.S. revenue rose 25% to $21.4 million, while international sales climbed 23% to $5.2 million, showing that growth is not dependent on any single geography.

Margin Expansion Signals Better Operating Leverage

Profitability metrics moved in the right direction, with gross profit jumping 37% year over year to $18.3 million. Gross margin expanded from 63% to 69%, a six‑percentage‑point gain that reflects both improved pricing and a richer product mix, giving investors evidence that scale is starting to translate into better unit economics.

Adjusted EBITDA Loss Narrows as Cash Burn Eases

The company’s adjusted EBITDA loss improved to $6.1 million from $9.1 million a year ago, a 32% improvement that shows tighter cost discipline. Butterfly ended the quarter with $138 million in cash and equivalents and used $12.5 million during the period, an improvement of 15% versus last year, extending its financial runway for strategic investments.

Embedded Business Emerges as a Growth Engine

Butterfly’s Embedded segment posted revenue of $5.7 million, up 147% year over year and now a material contributor to the top line. Management credited the Midjourney partnership for most of the surge and framed Embedded as a key long‑term growth driver as more partners integrate Butterfly’s imaging technology into their own solutions.

Premium POCUS Devices Drive Higher Selling Prices

Point‑of‑care ultrasound hardware performance was mixed but skewed toward higher value products, with overall probe unit sales up 5% in the quarter. A strong shift to the higher‑end iQ3 device drove an 11% year‑over‑year increase in average selling price, as iQ3 sales jumped 39%, underscoring growing demand for advanced capabilities.

Breakthrough FDA Clearance for Gestational Age AI

A highlight of the quarter was Butterfly’s first‑ever FDA clearance for a blind‑sweep gestational age AI tool, capable of estimating fetal age in about two minutes. Trained on roughly 21 million images and publicly highlighted by the regulator, this approval strengthens the company’s AI credentials and could open new use cases in obstetric care.

Software Ecosystem and Enterprise Deals Gain Traction

The Butterfly Garden ecosystem expanded to 30 partners after two new additions, and four partners now have received their own FDA clearances, validating the platform. The Compass AI pipeline grew sharply year over year, and the company closed its first enterprise software deal with a seven‑figure total contract value, signaling rising software monetization.

Education and Enterprise Channels Build Future Demand

Butterfly continued seeding future demand by selling nearly 1,000 probes this year into medical school programs across six institutions, embedding its tools in clinician training. Early enterprise adoption of Compass AI is underway, with management expecting this channel to become a more meaningful revenue contributor in 2026 as deployments scale.

Security Credentials Unlock Larger Health and Federal Deals

Management highlighted new security achievements, including obtaining HITRUST r2 certification, a key requirement for many large health systems. Butterfly also entered the FedRAMP marketplace process with sponsorship from the Department of Veterans Affairs, positioning the company to pursue future federal contracts once fully authorized.

Product and Platform Roadmap Targets Multi‑Year Catalysts

Looking ahead, the company is leaning on its Apollo chip and expanding Embedded roadmap as core revenue catalysts, aided by a ninth Embedded partner and more expected to follow. Butterfly also outlined plans for a new probe early next year and a station product targeted for early‑to‑mid 2027, signaling a steady cadence of platform enhancements.

Home and Community Care Offer Longer‑Term Upside

Butterfly’s Home and Community Care initiative remains early but promising, with management planning a first commercial agreement in the first half of 2026. The roadmap calls for an initial statewide deployment and nurse training in the third quarter of that year, with first revenue contributions in the second half of 2026 and broader expansion into 2027.

Persistent Losses and Product Mix Headwinds Remain

Despite progress, profitability is still negative, with an adjusted EBITDA loss of $6.1 million this quarter and full‑year 2026 losses still expected amid ongoing investments. Lower‑tier iQ+ probe sales fell 43% year over year, increasing reliance on higher‑margin iQ3 volume to sustain average selling price gains and unit growth.

Embedded Growth and EU Rules Add Execution Risk

The Embedded surge was driven mainly by a single large partnership, creating concentration risk and emphasizing the importance of adding more scaled partners over time. In Europe, regulators recommended extending the handheld ultrasound RoHS lead exemption for only two years, shorter than typical, creating interim uncertainty around future regulatory requirements.

Cash Usage and Macro Factors Require Discipline

While cash burn improved, using $12.5 million in the quarter keeps the focus on capital discipline as Butterfly balances growth with its finite cash pool. Management also flagged potential minor impacts from geopolitical events and tariffs, plus execution risk around new initiatives like Home, Embedded integrations, and large enterprise deals.

Guidance Points to Continued Growth and Ongoing Investment

For the second quarter, Butterfly guided revenue between $27 million and $31 million, implying roughly 24% year‑over‑year growth at the midpoint, alongside an adjusted EBITDA loss of $6 million to $8 million. The company reaffirmed full‑year 2026 targets for $117 million to $121 million in revenue and an adjusted EBITDA loss of $21 million to $25 million, embedding continued investment in Compass AI, Embedded solutions, and Home and Community Care.

Overall, Butterfly Network’s call painted a picture of a company transitioning from a hardware‑only story into a broader AI‑enabled platform with growing recurring and embedded revenue. Investors will need to weigh strong growth, margin expansion, and regulatory wins against ongoing losses, concentration risk, and macro uncertainty, but management’s reaffirmed guidance suggests confidence in the multi‑year trajectory.